Seletracetam
As of the edition of 20 October 2026, Seletracetam is a small molecule: stopped in 2012; acts on SV2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2012
- Kind
- Small molecule
- Registered trials
- 5, 3 stopped early
- Disease areas
- Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SV2A | Synaptic vesicle glycoprotein 2A | Q7L0J3 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 0 | 0 | 3 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| UCB | Lead sponsor of trials | 2005 to now |